Brief: Knight Therapeutics Announces CMED Price Approval Of Minjuvi In Brazil
16/10/2023 12:57
Oct 16 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES CMED PRICE APPROVAL OF
MINJUVI®
(TAFASITAMAB) IN BRAZIL
* KNIGHT THERAPEUTICS INC - EXPECTS TO LAUNCH MINJUVI® IN
BRAZIL
IN Q2 OF 2024
* KNIGHT THERAPEUTICS INC - WITH PRICE APPROVAL MINJUVI®
WILL BE
AVAILABLE FOR COMMERCIALIZATION IN BRAZILIAN MARKET
Source text for Eikon: ID:nGNX8L1jl3
Further company coverage: GUD.TO
(Reuters.Briefs@thomsonreuters.com)
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil